Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preventive Effect of Clopidogrel on Systemic Sclerosis Development Risk
NCT05098704Phase 3Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jun 2022
- Primary completion
- Jun 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of clopidogrel in systemic sclerosis (SSc), sponsored by Centre Hospitalier Universitaire de Bordeaux. Started Jun 2022; status: recruiting.
02
Drugs
clopidogrel
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT05098704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05098704.